The present invention refers to human EGLN2 variants having at position 58 of the amino acid sequence a serine or a leucine and their use in the prevention or treatment of thromboembolic or coronary heart diseases, in particular stroke, prolonged reversible ischemic neurological deficit (PRIND), transitoric ischemic attack (TIA), myocardial infarction and/or early myocardial infarction.本發明乃有關於胺基酸序列位置58具有絲胺酸或白胺酸之人類EGLN2變體,及其於治療或預防血栓栓塞性或冠狀心臟疾病特別是中風、長期之可逆性缺血性神經缺損(PRIND)、短暫性腦缺血發作(TIA)、心肌梗塞及/或早期心肌梗塞之用途。
